ORYZF Financials: Oryzon Genomics SA AI Analysis

Home

Stock

ORYZF

Financials

ORYZF Financial

Oryzon Genomics SA

$3.34

At close: Mar 27, 16:00:00 GMT-4

$3.34

Post-market: Mar 27, 20:00:00 GMT-4

Overview Forecast Earnings Dividends Financials

Income

Balance sheet

Cash flow

Annual

Quarterly

ORYZF Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021
Revenue	0	0	0	0	0	0
Revenue Growth (YoY)	--	--	--	--	--	--
Cost of Revenue	1	1	1	1	2	3
Gross Profit	-1	-1	-1	-1	-2	-3
Selling, General & Admin	4	4	3	3	3	3
Research & Development	--	--	--	--	--	--
Operating Expenses	3	3	3	3	3	3
Other Non Operating Income (Expenses)	--	--	--	--	--	--
Pretax Income	-5	-5	-5	-6	-6	-7
Income Tax Expense	-2	-2	-1	-2	-2	-2
Net Income	-2	-2	-3	-3	-4	-4
Net Income Growth	-33%	-33%	0%	-25%	0%	33%
Shares Outstanding (Diluted)	77.51	77.51	64.74	60.87	55.29	52.76
Shares Change (YoY)	10%	20%	6%	10%	5%	0%
EPS (Diluted)	-0.03	-0.03	-0.05	-0.05	-0.07	-0.09
EPS Growth	-32%	-39%	0%	-28%	-15%	50%
Free Cash Flow	-13	-13	-13	-15	-16	-15
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	0%	0%	0%	0%	0%	0%
Operating Margin	0%	0%	0%	0%	0%	0%
Profit Margin	0%	0%	0%	0%	0%	0%
Free Cash Flow Margin	0%	0%	0%	0%	0%	0%
EBITDA	-5	-5	-4	-4	-5	-7
EBITDA Margin	0%	0%	0%	0%	0%	0%
D&A For EBITDA	0	0	0	0	0	0
EBIT	-5	-5	-4	-4	-5	-7
EBIT Margin	0%	0%	0%	0%	0%	0%
Effective Tax Rate	40%	40%	20%	33.33%	33.33%	28.57%

Follow-Up Questions

What are Oryzon Genomics SA's key financial statements?



According to the latest financial statement (Form-10K), Oryzon Genomics SA has a total asset of $144, Net loss of $-2

What are the key financial ratios for ORYZF?



Oryzon Genomics SA's Current ratio is 5.53, has a Net margin is 0, sales per share of $0.

How is Oryzon Genomics SA's revenue broken down by segment or geography?



Oryzon Genomics SA largest revenue segment is Advertising, at a revenue of 196,175,000,000 in the most earnings release.For geography, United States and Canada is the primary market for Oryzon Genomics SA, at a revenue of 78,866,000,000.

Is Oryzon Genomics SA profitable?



no, according to the latest financial statements, Oryzon Genomics SA has a net loss of $-2

Does Oryzon Genomics SA have any liabilities?



yes, Oryzon Genomics SA has liability of 26

How many outstanding shares for Oryzon Genomics SA?



Oryzon Genomics SA has a total outstanding shares of 77.51

Key Stats

Prev.Close

$3.34

Open

$3.03

Day's Range

$3.03 - $3.34

52 week range

$3.03 - $4.37

Volume

5.0K

Avg.Volume

135

Dividend yield

EPS (TTM)

-0.04

Market Cap

$266.8M

What is ORYZON GENOMICS SA?

Oryzon Genomics SA is a clinical stage biopharmaceutical company, which engages in the discovery, research, and development of new chemical entities, as well as conducting clinical trials. The company is headquartered in Cornella De Llobregat, Barcelona and currently employs 44 full-time employees. The company went IPO on 2015-12-10. Its compounds in clinical development include iadademstat (ORY-lOOl), an LSD1 inhibitor that is in Phase II trials for the treatment of acute myeloid leukemia and small cell lung cancer; and vafidemstat (ORY-2001), an LSD1 inhibitor optimized for the Central Nervous System (CNS), in multiple Phase II clinical trials for the treatment of CNS and psychiatric illnesses. The firm also has ORY-3001, in preclinical development for the treatment of non-oncological diseases and has additional programs to develop inhibitors against other epigenetic targets.



Features

AI Copilot for Stock & Crypto

Resources